Loading...

Jonathan Wesley Riess

TitleASST PROF OF CLIN-HCOMP
InstitutionUniversity of California Davis
DepartmentHematology and Oncology
AddressCancer Ctr So #3016
CA 95817
Phone916-734-3772
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Riess JW, Gandara DR, Frampton GM, Madison R, Peled N, Bufill JA, Dy G, Ignatius Ou SH, Stephens PJ, McPherson J, Lara PN, Burich RA, Ross JS, Miller VA, Ali SM, Mack PC, Schrock AB. Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of Non-Small Cell Lung Cancer. J Thorac Oncol. 2018 Jul 05. PMID: 29981927.
      View in: PubMed
    2. Gandara DR, Riess JW, Lara PN. In Search of an Oncogene Driver for Squamous Lung Cancer. JAMA Oncol. 2018 Jun 14. PMID: 29902311.
      View in: PubMed
    3. Rolfo C, Mack PC, Scagliotti GV, Baas P, Barlesi F, Bivona TG, Herbst RS, Mok TS, Peled N, Pirker R, Raez LE, Reck M, Riess JW, Sequist LV, Shepherd FA, Sholl LM, Tan DS, Wakelee HA, Wistuba II, Wynes MW, Carbone DP, Hirsch FR, Gandara DR. IASLC Statement Paper: Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC). J Thorac Oncol. 2018 Jun 06. PMID: 29885479.
      View in: PubMed
    4. Leonardi GC, Gainor JF, Altan M, Kravets S, Dahlberg SE, Gedmintas L, Azimi R, Rizvi H, Riess JW, Hellmann MD, Awad MM. Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders. J Clin Oncol. 2018 May 10; JCO2017770305. PMID: 29746230.
      View in: PubMed
    5. Ma BBY, Lim WT, Goh BC, Hui EP, Lo KW, Pettinger A, Foster NR, Riess JW, Agulnik M, Chang AYC, Chopra A, Kish JA, Chung CH, Adkins DR, Cullen KJ, Gitlitz BJ, Lim DW, To KF, Chan KCA, Lo YMD, King AD, Erlichman C, Yin J, Costello BA, Chan ATC. Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742). J Clin Oncol. 2018 May 10; 36(14):1412-1418. PMID: 29584545.
      View in: PubMed
    6. Floc'h N, Martin MJ, Riess JW, Orme JP, Staniszewska AD, Ménard L, Cuomo ME, O'Neill DJ, Ward RA, Finlay MRV, McKerrecher D, Cheng M, Vang DP, Burich RA, Keck JG, Gandara DR, Mack PC, Cross DAE. Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions. Mol Cancer Ther. 2018 May; 17(5):885-896. PMID: 29483211.
      View in: PubMed
    7. Padda SK, Yao X, Antonicelli A, Riess JW, Shang Y, Shrager JB, Korst R, Detterbeck F, Huang J, Burt BM, Wakelee HA, Badve SS. Paraneoplastic Syndromes and Thymic Malignancies: An Examination of the International Thymic Malignancy Interest Group Retrospective Database. J Thorac Oncol. 2018 Mar; 13(3):436-446. PMID: 29191778.
      View in: PubMed
    8. Blakely CM, Watkins TBK, Wu W, Gini B, Chabon JJ, McCoach CE, McGranahan N, Wilson GA, Birkbak NJ, Olivas VR, Rotow J, Maynard A, Wang V, Gubens MA, Banks KC, Lanman RB, Caulin AF, St John J, Cordero AR, Giannikopoulos P, Simmons AD, Mack PC, Gandara DR, Husain H, Doebele RC, Riess JW, Diehn M, Swanton C, Bivona TG. Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers. Nat Genet. 2017 Dec; 49(12):1693-1704. PMID: 29106415.
      View in: PubMed
    9. Lara JD, Brunson A, Riess JW, Kelly K, Lara PN, Gandara DR. Clinical predictors of survival in young patients with small cell lung cancer: Results from the California Cancer Registry. Lung Cancer. 2017 Oct; 112:165-168. PMID: 29191590.
      View in: PubMed
    10. Gautschi O, Milia J, Filleron T, Wolf J, Carbone DP, Owen D, Camidge R, Narayanan V, Doebele RC, Besse B, Remon-Masip J, Janne PA, Awad MM, Peled N, Byoung CC, Karp DD, Van Den Heuvel M, Wakelee HA, Neal JW, Mok TSK, Yang JCH, Ou SI, Pall G, Froesch P, Zalcman G, Gandara DR, Riess JW, Velcheti V, Zeidler K, Diebold J, Früh M, Michels S, Monnet I, Popat S, Rosell R, Karachaliou N, Rothschild SI, Shih JY, Warth A, Muley T, Cabillic F, Mazières J, Drilon A. Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry. J Clin Oncol. 2017 May 01; 35(13):1403-1410. PMID: 28447912.
      View in: PubMed
    11. Gandara DR, Riess JW, Kelly K, Li T, Mack PC, Lara PN. Evolution and Increasing Complexity of the Therapeutic Landscape in Advanced Non-Small-cell Lung Cancer. Clin Lung Cancer. 2017 01; 18(1):1-4. PMID: 28082049.
      View in: PubMed
    12. Riess JW, Lara PN, Gandara DR. Theory Meets Practice for Immune Checkpoint Blockade in Small-Cell Lung Cancer. J Clin Oncol. 2016 Nov 01; 34(31):3717-3718. PMID: 27601544.
      View in: PubMed
    13. Parikh M, Riess J, Lara PN. New and emerging developments in extensive-stage small cell lung cancer therapeutics. Curr Opin Oncol. 2016 Mar; 28(2):97-103. PMID: 26844984.
      View in: PubMed
    14. Daly ME, Riess JW. Multidisciplinary Care. Cancer Treat Res. 2016; 170:285-300. PMID: 27535399.
      View in: PubMed
    15. Padda SK, Shrager JB, Riess JW, Pagtama JY, Holmes Tisch AJ, Kwong BY, Liang Y, Schwartz EJ, Loo BW, Neal JW, Hardy R, Wakelee HA. Pruritus as a Paraneoplastic Symptom of Thymoma. J Thorac Oncol. 2015 Nov; 10(11):e110-2. PMID: 26536199; PMCID: PMC4720251.
    16. Hrustanovic G, Olivas V, Pazarentzos E, Tulpule A, Asthana S, Blakely CM, Okimoto RA, Lin L, Neel DS, Sabnis A, Flanagan J, Chan E, Varella-Garcia M, Aisner DL, Vaishnavi A, Ou SH, Collisson EA, Ichihara E, Mack PC, Lovly CM, Karachaliou N, Rosell R, Riess JW, Doebele RC, Bivona TG. RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer. Nat Med. 2015 Sep; 21(9):1038-47. PMID: 26301689; PMCID: PMC4734742.
    17. Gandara DR, Mack PC, Bult C, Li T, Lara PN, Riess JW, Astrow SH, Gandour-Edwards R, Cooke DT, Yoneda KY, Moore EH, Pan CX, Burich RA, David EA, Keck JG, Airhart S, Goodwin N, de Vere White RW, Liu ET. Bridging tumor genomics to patient outcomes through an integrated patient-derived xenograft platform. Clin Lung Cancer. 2015 May; 16(3):165-72. PMID: 25838158; PMCID: PMC4586173.
    18. Padda SK, Riess JW, Schwartz EJ, Tian L, Kohrt HE, Neal JW, West RB, Wakelee HA. Diffuse high intensity PD-L1 staining in thymic epithelial tumors. J Thorac Oncol. 2015 Mar; 10(3):500-8. PMID: 25402569; PMCID: PMC4720257.
    19. Riess JW, West R, Dean M, Klimowicz AC, Neal JW, Hoang C, Wakelee HA. GLI1, CTNNB1 and NOTCH1 protein expression in a thymic epithelial malignancy tissue microarray. Anticancer Res. 2015 Feb; 35(2):669-76. PMID: 25667444.
      View in: PubMed
    20. Riess JW, Lara PN. Left behind? Drug discovery in extensive-stage small-cell lung cancer. Clin Lung Cancer. 2014 Mar; 15(2):93-5. PMID: 24529447; PMCID: PMC4184801.
    21. Riess JW, Nagpal S, Iv M, Zeineh M, Gubens MA, Ramchandran K, Neal JW, Wakelee HA. Prolonged survival of patients with non-small-cell lung cancer with leptomeningeal carcinomatosis in the modern treatment era. Clin Lung Cancer. 2014 May; 15(3):202-6. PMID: 24524822.
      View in: PubMed
    22. Gandara DR, Li T, Lara PN, Kelly K, Riess JW, Redman MW, Mack PC. Acquired resistance to targeted therapies against oncogene-driven non-small-cell lung cancer: approach to subtyping progressive disease and clinical implications. Clin Lung Cancer. 2014 Jan; 15(1):1-6. PMID: 24176733; PMCID: PMC4586161.
    23. Lwin Z, Riess JW, Gandara D. The continuing role of chemotherapy for advanced non-small cell lung cancer in the targeted therapy era. J Thorac Dis. 2013 Oct; 5 Suppl 5:S556-64. PMID: 24163748; PMCID: PMC3804876.
    24. Jahchan NS, Dudley JT, Mazur PK, Flores N, Yang D, Palmerton A, Zmoos AF, Vaka D, Tran KQ, Zhou M, Krasinska K, Riess JW, Neal JW, Khatri P, Park KS, Butte AJ, Sage J. A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors. Cancer Discov. 2013 Dec; 3(12):1364-77. PMID: 24078773.
      View in: PubMed
    25. Ho C, Davies AM, Sangha RS, Lau D, Lara P, Chew HK, Beckett L, Mack PC, Riess JW, Gandara DR. Phase I/II trial of pemetrexed plus nab-paclitaxel in advanced solid tumor patients with emphasis on non-small cell lung cancer. Invest New Drugs. 2013 Dec; 31(6):1587-91. PMID: 24013936; PMCID: PMC4562389.
    26. Riess JW, Nagpal S, Das M, Neal JW, Kim JW, Wakelee HA. A case series of NSCLC patients with different molecular characteristics and choroidal metastases: improvement in vision with treatment including pemetrexed and bevacizumab. J Thorac Oncol. 2013 Feb; 8(2):e17-8. PMID: 23328555; PMCID: PMC3552378.
    27. Riess JW, Neal JW. Targeting fibroblast growth factor receptor and discoidin domain receptor 2 in non-small-cell lung cancer. J Thorac Oncol. 2012 Dec; 7(16 Suppl 5):S385-6. PMID: 23160327.
      View in: PubMed
    28. Riess JW, Neal JW. Targeting FGFR, ephrins, Mer, MET, and PDGFR-a in non-small cell lung cancer. J Thorac Oncol. 2011 Nov; 6(11 Suppl 4):S1797-8. PMID: 22005534.
      View in: PubMed